OVID Ovid Therapeutics Inc
5,750
$3.11
$0.03
(0.95%)
| Watchers | 5,750 |
| 52-Wk Low | $2.57 |
| 52-Wk High | $4.14 |
| Market Cap | $220.64M |
| Volume | 41,552.00 |
| 52-Wk High | $4.14 |
| 52-Wk Low | $2.57 |
Cracking The Code: Understanding Analyst Reviews For Ovid TherapeuticsBenzinga • 14 days ago
Latest Ratings for OVID
DateFirmActionFromTo Aug 2021CitigroupMaintainsNeutral Apr 2021Cantor FitzgeraldDowngradesOverweightNeutral Dec 2020CitigroupDowngradesBuyNeutral
View More Analyst...
Share to Feed
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
This is a Bullish indicator signaling OVID's price could rise from here. Traders may explore going long the stock or buying call options...
This is a signal that OVID's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
In a report released yesterday, Ritu Baral from TD Cowen maintained a Buy rating on Ovid Therapeutics (OVID Research Report). The company's share...
Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or...
Related Stocks: FRA:1OT...
Related Stocks: FRA:1OT...
Related Stocks: FRA:1OT...